Investment Test Drive

DXNLX Direxion Monthly NASDAQ-100® Bll 1.25X

2 lower fee alternatives found

FeeX scanned the market for similar funds with lower fees and better past returns
Show results with
Investing
$
  YOU ASKED ABOUT FEATURED ALTERNATIVE ? ALTERNATIVE
Fund DXNLX Direxion Monthly NASDAQ-100® Bll 1.25X SPUU Direxion Daily S&P 500® Bull 2X ETF PILL Direxion Daily Pharmctcl&Medcl Bl 2X ETF  
Similarity
?
100% 86% 85%
Annual Fees
?
$140.42
(1.32% Exp. Ratio)
$67.02
(0.63% Exp. Ratio)
$86.17
(0.81% Exp. Ratio)
Future Est. Balance in 30 yrs
Assuming 6.38% annual return
$42,951.66 $52,937.63 $50,135.17
Est. savings over 30 yrs +$9,985.96 +$7,183.50
Return
As of 12/31/16
1 YR RETURN --
3 YR --
5 YR --
10 YR --
1 YR RETURN 20.93%
3 YR --
5 YR --
10 YR --
1 YR RETURN -39.11%
3 YR --
5 YR --
10 YR --
Description
The investment seeks monthly investment results, before fees and expenses, of 125% of the calendar month performance of the NASDAQ 100® Index. The fund, under normal circumstances, invests at least 80% of its net assets (plus borrowing for investment purposes) in financial instruments that provide leveraged exposure to the NASDAQ 100® Index (the "index") and/or ETFs that track the index. The index includes 100 of the largest domestic and international non-financial companies listed on the NASDAQ Stock Market® based on market capitalization. All companies in the index have an average daily trading volume of at least 200,000 shares. The fund is non-diversified.
The investment seeks daily investment results, before fees and expenses, of 200% of the performance of the S&P 500® Index. The fund, under normal circumstances, creates long positions by investing at least 80% of its assets in the securities that comprise the S&P 500® Index and/or financial instruments that provide leveraged and unleveraged exposure to the index. The index is a capitalization-weighted index composed of 500 common stocks. Standard & Poor's® selects the 500 stocks comprising the index on the basis of market values and industry diversification. The fund is non-diversified.
The investment seeks daily investment results, before fees and expenses, of 200% of the performance of the Dynamic Pharmaceutical Intellidex Index. The fund, under normal circumstances, creates long positions by investing at least 80% of its assets in the securities that comprise the Dynamic Pharmaceutical Intellidex Index and/or financial instruments that provide leveraged and unleveraged exposure to the index. The index consists of common shares of U.S. pharmaceutical companies. These companies are principally engaged in research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.

Join FeeX to view all alternatives, get more data and filtering options, and be able to automatically scan all your investments for lower fee replacements.

It's free!

The fees, balance and savings information above are estimated numbers, based on the data FeeX had at the day of publication, but may not be accurate due to incomplete or erroneous data.

The best choice is based on a combined analysis of lowest fees and highest similarity to the original fund.

Similarity

FeeX's similarity algorithm analyzes over 15 investment characteristics like investment category, asset allocation, strategy, geographical allocation and more. FeeX gives each its own weight and calculates the similarity of any two investments based on a scale of 0 to 100%. Funds with a similarity ranking of 85% and higher are considered "similar".

Yes, funds and ETFs charge fees

Deep within every fund you own lies a hidden fee called expense ratio. It takes away a set % of your savings each and every year. It can often be easily reduced by switching to similar investments with lower expense ratios.

+

Your Feedback has been sent successfully!